**2021 APEC Business Ethics for SMEs Forum Agenda**

|  |
| --- |
| 27 July | Emerging Ethical Decision Frameworks for Patient Data *60 min.* * + Speakers:
		- **Cecilia Rodriguez**, Executive Director, Fundación Me Muevo
		- **Natalie Evans Harris**, Senior Advisor for Delivery, U.S. Department of Commerce
		- **Sobia Akram,** Corporate Vice President of Global Business Ethics, Novo Nordisk
		- **Venk Varadan,** Co-founder and CEO, Nanowear

*Link to Unlisted Recording:* [*https://youtu.be/JRXsqBprTWI*](https://youtu.be/JRXsqBprTWI) |

|  |
| --- |
| 7 September | 2021 Code of Ethics Implementation Survey Results *30 min*.* + Speakers:
		- **Medical Technology Sector: Nancy Travis**, Vice President, Global Compliance & Governance, AdvaMed
		- **Biopharmaceutical Sector: Lama Abi Khaled**, Executive Director of Ethics, Legal, and Regulatory, Innovative Medicines Canada

*Link to Unlisted Recording:* [*https://youtu.be/37lCfSetJYA*](https://youtu.be/37lCfSetJYA) |

|  |
| --- |
| 16 September | Capacity Building: APEC Principles in Action *60 min.*Global Distributor Compliance Toolkit (30 minutes)* *Introduction*: **Nancy Travis**, Vice President, Global Compliance & Governance, AdvaMed
* *Asia Pacific Medical Technology Association (APACMed) Implementation*: **Nieves Liste,** Senior Director, Global Channel Compliance and EMEA Compliance, Medtronic
* *China Implementation:* **Lynn Jiao,** Vice President & China Executive Director, AdvaMed China
* *Japan Implementation:* **Katsumi Kojima,** International Business Working Group Leader, Japan Federation of Medical Device Association (JFMDA)

APEC SME Leaders in Ethics & Integrity Program (LEIP) (30 minutes) * *Introduction*: **Karen Eryou**, Chief of Staff, Enterprise Risk and International Markets Legal, Ethics & Compliance, UCB Pharma & Chair, IGO Working Group, Ethics and Business Integrity Committee, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
* *Outcomes from Chile:***Vicente Astorga**, General Manager, Droguería Farmoquímica del Pacífico and President, Cámara Nacional de Laboratorios (Chile)
* *Outcomes from Canada*: **Chrisoula Nikidis,** Head of Ethics & Compliance Policy Shaping, Global Ethics and Compliance, Takeda

 *Link to Unlisted Recording:* [*https://youtu.be/YOGmnNEFfS4*](https://youtu.be/YOGmnNEFfS4) |

|  |
| --- |
| 21 September | Patient Roundtable *60 min.* Chaired by:* + **Russell Williams**, Patient Co-Chair, APEC Biopharmaceutical Working Group on Ethics / Vice President, Diabetes Canada

Agenda**1. Scene setting: Where we have been and where we are** * + - Overview of Vision 2025 and Patient Workplan
		- APEC Modernized Principles

**2. Patient Network Implementation of Vision 2025*** + - How can patient organizations support the implementation of the APEC modernized principles, including participation in capacity building programs and annual monitoring?
		- How can patients and patient organizations support the adoption of consensus frameworks in each APEC economy by 2023 and implementation by 2025?
		- How can patients lend their voice to health ethics, including emerging issues, through applied capacity-building for leadership and communications?
 |

|  |
| --- |
| 21 September | APEC Healthcare Professionals Network Roundtable *60 min.*Chaired by:* + **Jeff Blackmer**, Executive Vice President, Global Health and Chief Medical Officer, Canadian Medical Association

Agenda **1. Where have we been and where are we?*** APEC KL and MC Principles Modernization
* Vision 2025 and HCP Action Plan

**2. Where are we going?*** *Health tech ethics* - Has your organization started to engage in discussions on global principles or standards for health technology ethics? In your view, what are the most important efforts needed to ensure HCPs develop appropriate standards for the future of technology ethics in the sector?
* *Government strategies to encourage ethical business conduct*- Is there one area in the Government Strategies to Encourage Ethical Business Conduct Guide that HCP leaders would like to focus?  (1) Convening Power, (2) Procurement, (3) Regulatory Practices, (4) Enforcement Recognitions and Incentives, (5) Government Supported Business Ethics Training, and (6) Trade Agreements.
 |

|  |
| --- |
| 27 September | Perspectives on Ethical Business Practices for Environmental, Social, and Corporate Governance (ESG) *60 Min.***Virtual Roundtable**Introduction* + **Sofie Melis**, Director, HR and Ethics & Compliance, IFPMA

Overview of Current ESG Discussions * + **Myrto Kontaxi,** Partner, Biopharma Sustainability Roundtable (BSRT)

Investor Perspectives * + **Shin Furuya**, Impact Investing Strategist, Domini Impact Investments
	+ **Rogier Snijdewind,** Director Active Ownership, Pension Fund for Care and Well-Being (Netherlands)

Industry Perspective* + **Lindsay Havern**, Vice President and Chief Compliance Counsel, Compliance Governance, Science, Supply and Corporate Affairs, Pfizer

Conclusion * + **Thomas Scheiwiller**, Co-Founder, Biopharma Sustainability Roundtable (BSRT)

*Link to Unlisted Recording:* [*https://youtu.be/ai\_tnMi8mAs*](https://youtu.be/ai_tnMi8mAs) |

|  |
| --- |
| 12 October | Plenary Session *90 Min.* * Plenary Overview here: [2021 APEC Business Ethics for SMEs Virtual Forum (eventtia.com)](https://live.eventtia.com/en/apecethics2021/Home)
* Final Plenary Recording: <https://vimeo.com/629499365/0a5451d97d>
 |